DEVELOPEMNT OF NOVEL DRUGS THAT TARGET COACTIVATION SITES OF THE ANDROGEN RESEPTOR FOR TREATMENT OF ANTIANDROGEN0RESISTANT PROSTATE CANCER

The University Of British Columbia

Investigators